+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Market Spotlight: Cutaneous T-Cell Lymphoma (CTCL)

  • ID: 4462166
  • Report
  • October 2020
  • Region: Global
  • 45 Pages
  • Datamonitor Healthcare

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • Acrotech Biopharma
  • Celgene
  • Ligand
  • Merck & Co.
  • Spectrum Pharmaceuticals
  • Takeda
This Market Spotlight report covers the Cutaneous T-Cell Lymphoma (CTCL) market, comprising key marketed and pipeline drugs, clinical trials, upcoming events, recent events and analyst opinion, probability of success, a 10-year disease incidence and prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

Key Takeaways

The publisher estimates that in 2017, there were approximately 15,200 incident cases of cutaneous T-cell lymphoma (CTCL) worldwide, and forecasts that number to increase to 18,060 incident cases by 2026.

In 2017, there were approximately 5,930 incident cases of CTCL in the US and five major European markets (France, Germany, Italy, Spain and the UK), which is forecast to increase to 6,160 incident cases by 2026.

The publisher estimates that there were approximately 41,900 10-year prevalent cases of CTCL in the US and five major European markets in 2017, which is expected to increase to 45,030 cases by 2026.

Approved drugs in the CTCL space target antibody-drug conjugate, cluster of differentiation 30, tumor necrosis factor receptor superfamily member 8, microtubules, histone deacetylase, interleukin-2, protein synthesis, chemokine receptor 4, retinoid X receptors, retinoid receptors, DNA, and DNA synthesis. These drugs are administered via the intravenous, topical, and oral routes.

The majority of industry-sponsored drugs in active clinical development for CTCL are in Phase II, with only one drug in Phase III. Therapies in development for CTCL focus on a wide variety of targets. The greatest proportion of pipeline drugs in development are administered intravenously, with the remainder being tested in oral, topical, intratumoral, and subcutaneous formulations.

High-impact upcoming events for drugs in the CTCL space comprise topline Phase II trial results for resminostat, AFM13, IPH4102, and cobomarsen.

The overall likelihood of approval of a Phase I hematologic asset is 9.4%, and the average probability a drug advances from Phase III is 60.3%. Drugs, on average, take 9.2 years from Phase I to approval, compared to 9.4 years in the overall oncology space.

The distribution of clinical trials across Phase I-IV indicates that the vast majority of trials for CTCL have been in the early and mid-phases of development, with 88% of trials in Phase I-II, and only 12% in Phase III-IV.

The US has a substantial lead in the number of CTCL clinical trials globally. Germany leads the major European markets, while Japan has the top spot in Asia.

Clinical trial activity in the CTCL space is dominated by completed trials. Bristol Myers Squibb has the highest number of completed clinical trials for CTCL, with six trials. Bristol Myers Squibb also leads the industry sponsors with the highest overall number of clinical trials for CTCL, followed by Merck & Co.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Acrotech Biopharma
  • Celgene
  • Ligand
  • Merck & Co.
  • Spectrum Pharmaceuticals
  • Takeda
OVERVIEW

KEY TAKEAWAYS

DISEASE BACKGROUND
  • Subtypes
TREATMENT
  • Skin-directed therapy
  • Systemic therapy
EPIDEMIOLOGY
  • Incidence methodology for the US and five major European markets
  • Prevalence methodology for the US and five major European markets
MARKETED DRUGS

PIPELINE DRUGS

RECENT EVENTS AND ANALYST OPINION
  • SGX301 for CTCL (April 30, 2020)
  • SGX301 for CTCL (March 19, 2020)
  • Copiktra for CTCL (July 25, 2019)
KEY UPCOMING EVENTS

KEY REGULATORY EVENTS
  • No English Funding For Lymphoma Drugs Ledaga and Poteligeo
PROBABILITY OF SUCCESS

LICENSING AND ASSET ACQUISITION DEALS
  • Almirall Gets Option To Buy Bioniz, Partners With 23andMe
REVENUE OPPORTUNITY

CLINICAL TRIAL LANDSCAPE
  • Sponsors by status
  • Sponsors by phase
BIBLIOGRAPHY
  • Prescription information
APPENDIX

List of Figures
  • Figure 1: Global trends in incident cases of CTCL, 2017-26
  • Figure 2: Trends in incident cases of CTCL, US and 5 Euro, 2017-26
  • Figure 3: Overview of pipeline drugs for CTCL in the US
  • Figure 4: Pipeline drugs for CTCL, by company
  • Figure 5: Pipeline drugs for CTCL, by drug type
  • Figure 6: Pipeline drugs for CTCL, by classification
  • Figure 7: SGX301 for CTCL (April 30, 2020): Phase III - FLASH
  • Figure 8: SGX301 for CTCL (March 19, 2020): Phase III - FLASH
  • Figure 9: Key upcoming events in CTCL
  • Figure 10: Probability of success in the CTCL pipeline
  • Figure 11: Clinical trials in CTCL
  • Figure 12: Top 10 drugs for clinical trials in CTCL
  • Figure 13: Top 10 companies for clinical trials in CTCL
  • Figure 14: Trial locations in CTCL
  • Figure 15: CTCL trials status
  • Figure 16: CTCL trials sponsors, by phase
List of Tables
  • Table 1: Global incident cases of CTCL, 2017-26
  • Table 2: Incident cases of CTCL, US and 5 Euro, 2017-26
  • Table 3: 10-year prevalent cases of CTCL, US and 5 Euro, 2017-26
  • Table 4: Five-year prevalent cases of CTCL, US and 5 Euro, 2017-26
  • Table 5: Marketed drugs for CTCL
  • Table 6: Pipeline drugs for CTCL in the US
  • Table 7: SGX301 for CTCL (April 30, 2020)
  • Table 8: SGX301 for CTCL (March 19, 2020)
  • Table 9: Copiktra for CTCL (July 25, 2019)
  • Table 10: Historical global sales, by drug ($m), 2015-19
  • Table 11: Forecasted global sales, by drug ($m), 2020-24
Note: Product cover images may vary from those shown
  • Acrotech Biopharma
  • Celgene
  • Ligand
  • Merck & Co.
  • Spectrum Pharmaceuticals
  • Takeda
Note: Product cover images may vary from those shown
Adroll
adroll